肺表面活性物质配伍NCPAP在新生儿呼吸窘迫中的应用

目的:探讨鼻塞式持续呼吸道正压通气(NCPAP)加肺表面活性物质(固尔苏)对早产儿呼吸窘迫综合征的治疗作用。方法:给31例患呼吸窘迫综合征的早产儿经气管内滴入肺表面活性物质固尔苏每次100~200m g/kg。然后拔管给予NCPAP呼吸支持治疗。结果:31例患儿在固尔苏给药后5m in呼吸窘迫明显缓解。其中16例NCPAP给氧1h后,11例NCPAP给氧2h后改用面罩给氧,并逐步撤氧。仅4例死亡。结论:NCPAP及肺表面活性物质能有效地治疗早产儿肺透明膜病,具有氧疗时间短等优点。

NCPAP and pulmonary surfactant for newborn with respiratory distress syndrome

Objective: To explore the treatment by nasal continuous positive airway pressure(NCPAP) and pulmonary surfactant(Curosurf) for newborn with respiratory distress syndrome.Methods: 31 cases of newborn with respiratory distress syndrome were treated by Curosurf(100～200mg/kg,every times) and then were given breath support by NCPAP.Results: The symptoms and signs of respiratory distress were evidntly relieved in all cases.After using NCPAP for 1h and 2h,16 cases and 11 cases were given veil oxygen respectively.There were only 4 deaths.Conclusion: NCPAP and pulmonary surfactant are effective and safe in newborn with respiratory distress syndrome,and can shorten oxygen therapy time.